In advanced non-small cell lung cancer (NSCLC), immune-checkpoint inhibitors targeting programmed cell death protein-1 (PD-1) can provide lasting treatment response and improve long-term survival [8,9]. Here, PDCD1 is linked to non-small cell lung carcinoma.